Correction: Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.

Correction: Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.

[This corrects the article DOI: 10.1371/journal.pone.0214387.].

Bibliographic Details
Main Author:	PLOS ONE Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0216535

Similar Items

Time course of western diet (WD) induced nonalcoholic steatohepatitis (NASH) in female and male Ldlr-/- mice.
by: Melinda H Spooner, et al.
Published: (2023-01-01)

Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible?
by: Kelli A Lytle, et al.
Published: (2016-01-01)

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.
by: Kelli A Lytle, et al.
Published: (2017-01-01)

A Lipidomic Analysis of Docosahexaenoic Acid (22:6, ω3) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male <i>Ldlr <sup>-/-</sup></i> Mice
by: Manuel García-Jaramillo, et al.
Published: (2019-10-01)

A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
by: Christopher M Depner, et al.
Published: (2013-01-01)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
by: Feryal Savari, et al.
Published: (2019-07-01)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
by: Elliot B. Tapper, et al.
Published: (2023-04-01)

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
by: Sebastião M.B. Duarte, et al.
Published: (2019-05-01)

Early transcriptome changes associated with western diet induced NASH in Ldlr−/− mice points to activation of hepatic macrophages and an acute phase response
by: Jyothi Padiadpu, et al.
Published: (2023-08-01)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
by: Xiaoyan Qi, et al.
Published: (2022-11-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
by: Hannah K. Drescher, et al.
Published: (2019-08-01)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
by: Saito Satoru, et al.
Published: (2008-11-01)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
by: Xinzhi Li, et al.
Published: (2021-12-01)

The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)
by: Noel Salvoza, et al.
Published: (2022-03-01)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
by: Alia Hadefi, et al.
Published: (2021-11-01)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
by: Hannah K. Drescher, et al.
Published: (2019-06-01)

Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in MiceSummary
by: Leonardo Vinicius Monteiro de Assis, et al.
Published: (2023-01-01)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
by: Naim Alkhouri, et al.
Published: (2018-01-01)

Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis
by: Vitor Jacó Antraco, et al.
Published: (2021-02-01)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
by: Simona Todisco, et al.
Published: (2022-05-01)

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
by: Eleftheria Galatou, et al.
Published: (2022-05-01)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
by: James Twiss, et al.
Published: (2023-07-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
by: Souradipta Ganguly, et al.
Published: (2021-01-01)

Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0
by: Mariapia Vairetti, et al.
Published: (2024-04-01)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
by: Mariapia Vairetti, et al.
Published: (2022-07-01)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
by: Tung-Sung Tseng, et al.
Published: (2023-09-01)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
by: Ivone Cristina Igreja Sá, et al.
Published: (2020-11-01)

Correction: Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.
by: PLOS ONE Staff
Published: (2021-01-01)

Correction: CD36/SR-B2-TLR2 Dependent Pathways Enhance Porphyromonas gingivalis Mediated Atherosclerosis in the Ldlr KO Mouse Model.
by: PLOS ONE Staff
Published: (2015-01-01)

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
by: Xi-Xi Wu, et al.
Published: (2021-11-01)

The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review
by: Jean-François Dufour, et al.
Published: (2021-06-01)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
by: José A. Inia, et al.
Published: (2023-05-01)

Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis
by: Hana Lastuvkova, et al.
Published: (2021-06-01)

Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF)
by: Guodong Zhang, et al.
Published: (2020-10-01)

Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs)
by: Isao Okazaki, et al.
Published: (2014-06-01)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
by: Elizabeth Clearfield, et al.
Published: (2021-05-01)

Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
by: Yuezhi Zhu, et al.
Published: (2023-05-01)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
by: Naim Alkhouri, et al.
Published: (2018-01-01)

Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr-/- Mice.
by: Mike L J Jeurissen, et al.
Published: (2016-01-01)